HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, A. E. Articles by Permpanich, B. Search for Related Content PubMed PubMed Citation Articles by Brown, A. E. Articles by Permpanich, B. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Malaria Occupational Health

Characteristics of Natural Antibody Responses to the Circumsporozoite Protein of Plasmodium Vivax

The antibody response to the prototype circumsporozoite (CS) protein of Plasmodium vivax (CSPV) was studied in Thai soldiers experiencing occupational malaria. Seventy-four (65%) of 114 men followed during assignment to a malaria transmission area developed blood-stage infection with P. vivax. IgG antibodies against the central repeat region of the CSPV protein were quantitated by ELISA using the recombinant protein, NS1₈₁V20, as the capture antigen. One quarter of the subjects had detectable anti-CSPV antibodies at the beginning of the study. CSPV antibody seroconversion was documented in 16 of 26 subjects assessed during their first observed episodes of vivax malaria. This antibody response was of moderate magnitude, fell off after the first week post-diagnosis and appeared, at the low levels observed, to be unassociated with protection. Continued assessment of anti-CSPV antibody after subjects left the transmission area found no increase associated with relapse of P. vivax. These findings indicate that CS antibody responses to P. vivax during occupational malaria share many characteristics with responses to P. falciparum.

This article has been cited by other articles:

				W. R. Ballou and C. P. Cahill Two Decades of Commitment to Malaria Vaccine Development: GlaxoSmithKline Biologicals Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 289 - 295. [Abstract] [Full Text] [PDF]